Figure 2. IFN‐γR1 knockout HSPCs display loss of IFN‐γ anti‐tumoral activity.

1. Engraftment of CD45.2 donor cells and lineage composition following transplantation of wild‐type (WT) or IFN‐γ receptor 1 knockout (KO) HSPCs transduced with either the control Tie2.NGFR (CTRL) or Tie2.IFN‐γ (IFN‐γ) LV (mean ± SD, each dot represents an individual mouse, WT CTRL = 7 mice, WT IFN‐γ = 7 mice, KO CTRL = 7 mice, KO IFN‐γ = 7 mice).
2. Vector copy number (VCN) in peripheral blood at 8 weeks post‐transplantation (mean ± SD, each dot represents an individual mouse).
3. B‐ALL progression measured as absolute number of OFP⁺ cells in the peripheral blood (mean ± SD, each dot represents an individual mouse; *P = 0.0286 at day 10; P = 0.0174 at day 12; ***P = 0.0002; ****P ≤ 0.0001; ordinary two‐way ANOVA).
4. MFI of MHC class II‐positive macrophages, identified by F4/80 expression, in the BM (mean ± SD, each dot represents an individual mouse; WT IFN‐γ vs. WT CTRL: *P = 0.0221, Mann–Whitney test).
5. Percentage of CD8⁺ T lymphocytes within OFP⁻ CD45⁺ BM cells (mean ± SD, each dot represents an individual mouse).
6. Maturation state (CD62L⁻CD44⁻ double negative, CD62L⁻CD44⁺ effector memory, CD62L⁺CD44⁻ naive and CD62L⁺CD44⁺ central memory T cells) of CD8⁺ lymphocytes (mean ± SD, each dot represents an individual mouse; WT IFN‐γ vs. WT CTRL: ****P ≤ 0.0001, ordinary one‐way ANOVA).

Data information: Statistical analysis of panel (C) is shown in Appendix Table S6.